abstract |
The invention provides novel methods for isolating, characterizing, comparing, and using biological components that are present in the cerebrospinal fluid. Such biological structures, called CS-MPs, can be used for identifying biomarkers that reflect the status (or anticipate the development) of disorders of the Central nervous System (CNS). The novel methods, biological products, and related kits make possible the use of CS-MPs and of their components as biomarkers for the diagnosis, prognosis, or monitoring of CNS disorders. The CS-MPs have a diameter comprised between 100 and 1000 nm and contain phosphatidylserine (PS). |